Literature DB >> 26277702

Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start.

Vinay Prasad1, Vance W Berger2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26277702      PMCID： PMC4567484          DOI： 10.1016/j.mayocp.2015.05.006

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  23 in total

1.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Authors:  Brian I Rini; Bernard Escudier; Piotr Tomczak; Andrey Kaprin; Cezary Szczylik; Thomas E Hutson; M Dror Michaelson; Vera A Gorbunova; Martin E Gore; Igor G Rusakov; Sylvie Negrier; Yen-Chuan Ou; Daniel Castellano; Ho Yeong Lim; Hirotsugu Uemura; Jamal Tarazi; David Cella; Connie Chen; Brad Rosbrook; Sinil Kim; Robert J Motzer
Journal:  Lancet       Date:  2011-11-04       Impact factor: 79.321

2.  Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Authors:  Tadeusz Robak; Huiqiang Huang; Jie Jin; Jun Zhu; Ting Liu; Olga Samoilova; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii Osmanov; Julia Alexeeva; Juliana Pereira; Johannes Drach; Jiri Mayer; Xiaonan Hong; Rumiko Okamoto; Lixia Pei; Brendan Rooney; Helgi van de Velde; Franco Cavalli
Journal:  N Engl J Med       Date:  2015-03-05       Impact factor: 91.245

3.  Run-in periods in randomized trials: implications for the application of results in clinical practice.

Authors:  A Pablos-Méndez; R G Barr; S Shea
Journal:  JAMA       Date:  1998-01-21       Impact factor: 56.272

Review 4.  Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Authors:  Giuseppe Di Lorenzo; Matteo Ferro; Carlo Buonerba
Journal:  BJU Int       Date:  2011-12-16       Impact factor: 5.588

5.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors:  Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal:  Lancet       Date:  2008-07-22       Impact factor: 79.321

6.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

Authors:  Michel Attal; Valerie Lauwers-Cances; Gerald Marit; Denis Caillot; Philippe Moreau; Thierry Facon; Anne Marie Stoppa; Cyrille Hulin; Lofti Benboubker; Laurent Garderet; Olivier Decaux; Serge Leyvraz; Marie-Christiane Vekemans; Laurent Voillat; Mauricette Michallet; Brigitte Pegourie; Charles Dumontet; Murielle Roussel; Xavier Leleu; Claire Mathiot; Catherine Payen; Hervé Avet-Loiseau; Jean-Luc Harousseau
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

7.  Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.

Authors:  Lilia Talarico; Gang Chen; Richard Pazdur
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

8.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

9.  Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.

Authors:  Jane Armitage; Louise Bowman; Rory Collins; Sarah Parish; Jonathan Tobert
Journal:  BMC Clin Pharmacol       Date:  2009-03-31

10.  Why most published research findings are false.

Authors:  John P A Ioannidis
Journal:  PLoS Med       Date:  2005-08-30       Impact factor: 11.613
View more
  9 in total

1.  Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.

Authors:  Talal Hilal; Miguel Gonzalez-Velez; Vinay Prasad
Journal:  JAMA Intern Med       Date:  2020-08-01       Impact factor: 21.873

2.  Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward.

Authors:  V Prasad; S V Rajkumar
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

3.  Marketing trials, marketing tricks - how to spot them and how to stop them.

Authors:  Alastair Matheson
Journal:  Trials       Date:  2017-03-08       Impact factor: 2.279

Review 4.  How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding.

Authors:  Michael P Hengartner
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-08

5.  Overcoming the Straw Man Effect in Oncology: Visualization and Ranking of Chemotherapy Regimens Using an Information Theoretic Approach.

Authors:  Jeremy L Warner; Peter C Yang; Gil Alterovitz
Journal:  JCO Clin Cancer Inform       Date:  2017-11

Review 6.  Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.

Authors:  Witold Lasek; Łukasz Zapała
Journal:  Cent European J Urol       Date:  2021-06-11

Review 7.  Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number.

Authors:  Simon Hawlina; Helena H Chowdhury; Tomaž Smrkolj; Robert Zorec
Journal:  Biol Direct       Date:  2022-02-23       Impact factor: 4.540

8.  Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials.

Authors:  Timothée Olivier; Vinay Prasad; Bernard L Marini
Journal:  Blood Adv       Date:  2022-06-14

9.  When is crossover desirable in cancer drug trials and when is it problematic?

Authors:  A Haslam; V Prasad
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 51.769
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.